Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:ENVB

Enveric Biosciences 8/14/2025 Earnings Report

Enveric Biosciences logo
$2.30 -0.02 (-0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$2.32 +0.02 (+0.65%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Enveric Biosciences EPS Results

Actual EPS
-$11.64
Consensus EPS
-$63.00
Beat/Miss
Beat by +$51.36
One Year Ago EPS
N/A

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enveric Biosciences Announcement Details

Quarter
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Enveric Biosciences' next earnings date is estimated for Monday, August 17, 2026, based on past reporting schedules.

Conference Call Resources

Enveric Biosciences Earnings Headlines

Enveric Biosciences (NASDAQ:ENVB) Raised to Sell at Wall Street Zen
May 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30794341
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
May 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/enveric-biosciences-reports-positive-preclinical-120000211.html
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
May 29 at 1:00 AM  |  InvestorPlace (Ad)
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519940575/en/enveric-biosciences-reports-positive-preclinical-results-from-phototoxicity-analysis-for-lead-neuroplastogen-candidate-eb-003/
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
May 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260505587393/en/enveric-biosciences-highlights-positive-results-for-eb-003-in-ptsd-preclinical-model/
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-appoints-joseph-tucker-phd-to-board-of-directors-302755046.html
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety. In parallel with pharmacology studies, the company is advancing formulation development, toxicology evaluations and analytical methods to support regulatory submissions and clinical trial readiness.

The company emphasizes a robust regulatory strategy and plans to file investigational new drug (IND) applications in the United States and Canada. Enveric collaborates with academic institutions, contract research organizations and clinical advisors to validate its drug candidates in emerging psychiatric therapy paradigms, including adjunctive use alongside psychotherapy.

Enveric Biosciences trades on the NASDAQ under the ticker ENVB, following a corporate rebranding from FSD Pharma in October 2021 to reflect its exclusive focus on psychedelic medicine. The company is pursuing strategic partnerships and geographic expansion across North America and Europe to accelerate clinical development and future commercialization of its pipeline assets.

View Enveric Biosciences Profile
Earnings Tools